We recently compiled a list of the 10 Best Reddit Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against the other stocks to buy according to Redditors.
Maintaining balance is essential in the current financial climate as uncertainties loom over both equity and bond markets. Investors are advised to stay informed and seek potential opportunities amid these changes. Recently, discussions have centered around the performance of mega-cap stocks, particularly in a bull market that has seen significant gains. As this bull market approaches its second anniversary, there is optimism regarding the future of AI and its impact on stock performance. Key players in the market are expected to continue driving growth, although at a potentially slower pace than in previous years.
Looking ahead, investors should prepare for a more gradual approach to interest rate cuts and reassess historical expectations regarding market dynamics. The ongoing economic shifts necessitate a diversified investment strategy focused on long-term growth potential, particularly for those new to investing. Emphasizing stocks with solid fundamentals and cash reserves may provide safer opportunities in an evolving landscape. Earlier in October, Malcolm Ethridge, Capital Area Planning Group managing partner, appeared on CNBC to discuss markets, particularly mega-cap stocks. We discussed his opinion in greater detail in our article on the 8 Best Stocks To Buy For Beginners Right Now, here’s an excerpt from it:
“When discussing the resilience of the two-year-old bull market, Ethridge highlighted that rising interest rates were initially expected to negatively impact market performance. However, despite facing historically high rates, the market has thrived. He noted that many leading companies, including some of the MAG7, have substantial cash reserves and are not reliant on borrowing to fund growth. This financial strength allows them to invest in AI technologies without being overly concerned about the Federal Reserve’s policies…
The conversation then shifted to expectations regarding future Fed rate cuts. Ethridge suggested that investors should prepare for a slower pace of rate cuts than previously anticipated. While a 25 basis point cut may occur at the next meeting, he indicated that there could be a prolonged period of stability afterward rather than a rapid series of cuts…”
READ ALSO: 10 Best Pharma Stocks To Buy Right Now and 10 AI News Investors Should Not Miss.
Strategies for Hedging and Investment
On October 30, RBC’s Amy Wu Silverman appeared on CNBC and outlined a strategy for investors to hedge risks in the equity markets, through the use of put options. Amy Wu Silverman thinks that investors have gotten long where they need to, and now they’re hedging positions. She provided insights into the current state of the options market, particularly focusing on mega-cap tech stocks, commonly called the MAG7. Silverman noted a stark contrast between H1 2024 and the current market sentiment in the latter half as the market gears up for significant earnings reports this week. In the earlier months, there was a notable exuberance among investors driven by fear of missing out on AI opportunities. This led to a surge in upside call buying. However, as of now, that trend has diminished, indicating that investors have largely established their positions and are now more focused on hedging their investments rather than aggressively pursuing new upside.
Silverman emphasized that while there is a general sense of bullishness surrounding these mega-cap tech names, many investors are seeking protection for their long positions. This protective stance is particularly relevant in a year where AI advancements have significantly influenced market performance. The conversation also highlighted the term “overhang,” which Silverman identified as her word of the day. This concept reflects the uncertainty surrounding upcoming major events, including earnings reports from megacap tech companies, the US presidential election scheduled for November 5, and Federal Open Market Committee (FOMC) meetings. She suggested that this overhang creates a challenging environment for investors as they navigate daily market fluctuations while anticipating future developments.
Silverman pointed out that investors are closely monitoring volatility expectations. A key metric in this regard is the Volatility Risk Premium, which measures how future expectations for volatility compare to actual market movements. Currently, this premium is substantial, indicating that traders expect heightened volatility in response to upcoming data releases and events. There is growing concern among investors about the possibility of not receiving an anticipated Fed rate cut if economic data comes in stronger than expected.
In addition to tech stocks, she discussed the oil market’s volatility amid geopolitical tensions in the Middle East. Silverman noted that there has been an increase in upside hedging related to these geopolitical risks. Investors are trying to determine whether the high volatility risk premium stems from political uncertainties or ongoing geopolitical factors impacting energy markets. To mitigate these risks, she recommended looking at energy proxies such as XOP or XEG in Canada as potential hedges against escalating geopolitical tensions.
Before concluding her remarks, Silverman shared a specific options trading strategy ahead of the election: S&P put spreads for November expiration. This strategy involves purchasing near-the-money put options while selling further out-of-the-money puts. Given the recent rally in the S&P 500 and the multitude of significant events on the horizon, she described this approach as an effective insurance mechanism against potential market downturns while capitalizing on current volatility conditions.
Methodology
We sifted through several threads to compile a list of the top 30 trending stocks. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q2 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 900 elite money managers.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly And Co. (NYSE:LLY)
Number of Hedge Fund Holders: 100
Eli Lilly And Co. (NYSE:LLY) is a major pharmaceutical company that develops and manufactures medicines. It specializes in treatments for various diseases, including diabetes, cancer, and mental health disorders. Some of its well-known drugs include insulin products, treatments for Alzheimer’s disease, and medications for autoimmune diseases. The company continues to invest heavily in research and development to address significant health challenges globally.
It had a strong third quarter for the year 2024, with revenue growing 42% after excluding the divested olanzapine portfolio. Overall revenue growth for the quarter was 20.43% and its revenue amounted to $11.44 billion. New products like Mounjaro and Zepbound, two weight loss medications, drove over $3 billion in growth, with strong US demand and expanding access. The company is on track to exceed the production target for incretin medicines, for the treatment of type 2 diabetes, in H2 2024.
While supply and channel dynamics impacted Q3 sales of Mounjaro and Zepbound, Eli Lilly And Co. (NYSE:LLY) is investing heavily to increase production and accelerate demand generation. The company is confident in its ability to exceed its production goals and drive future growth.
PGIM Jennison Health Sciences Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter:
“Eli Lilly and Company (NYSE:LLY) is a diversified biopharmaceutical company with core franchises in Diabetes, Obesity, Immunology, Neurodegeneration, and Oncology. The company is one of the two global leaders in diabetes with blockbuster products in Trulicity and recently launched Mounjaro (tirzepatide) to serve this large underserved market. To date, the Mounjaro launch is the strongest for any diabetes drug ever launched, which we attribute to off label usage in the obesity indication as well as on label use in diabetes. We believe the tirzepatide (the generic name for Mounjaro) franchise is also uniquely positioned to grow substantially from here thanks to its recent approval for obesity. To that note, in late 2023, Eli Lilly received approval for tirzepatide in obesity and is commercializing it for obesity under a new brand name, Zepbound. While still early in the launch, uptake has been extremely strong, exceeding that of both Wegovy and Mounjaro at the same timepoint in their launches. While Alzheimer’s Disease has been a tough market for drug developers, Eli Lilly has breakthrough designation from the food and drug administration (FDA) for donanemab and recently presented Phase III pivotal trial data that positions donanemab as the most efficacious drug in the class. In June, the FDA advisory committee voted unanimously in favor of donanemab as an effective treatment where the benefits outweigh the risks, praising the therapy as innovative. Donanemab was then approved under the brand name Kisunla in early July. Eli Lilly also has exciting franchises in dermatology, immunology, and oncology that are starting to add meaningfully to growth. With a proven history of strong commercial execution and one of the highest research and development (R&D) success rates in the industry, we see opportunity for continued success. With a lack of meaningful patent expirations for the rest of the decade. Eli Lilly is uniquely positioned amongst its larger-cap peers. Recent positive performance has been driven by the continued strong growth of Mounjaro and Zepbound, which led to a big guidance raise on the 1Q call, an unusual action for Eli Lilly this early in the year, which speaks to their confidence in the strong trends they are seeing.”
Overall LLY ranks 8th on our list of the stocks to buy according to Redditors. As we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
